Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage
Autor: | Burkhard Mai, Sabine Blaschke, Boris Schminke, Sandra Trautmann, Nicolai Miosge |
---|---|
Rok vydání: | 2015 |
Předmět: |
0301 basic medicine
Male Short Communication Immunology Inflammation Core Binding Factor Alpha 1 Subunit Biology Antibodies Monoclonal Humanized Proinflammatory cytokine Arthritis Rheumatoid Immunomodulation 03 medical and health sciences Cartilage Chondrogenesis Chondrogenic progenitor cells Rheumatoid arthritis Interleukin 17 (IL-17) medicine Immunology and Allergy Humans Progenitor cell Antibodies Blocking Cells Cultured Interleukin 3 Aged Receptors Interleukin-17 Stem Cells Interleukin-17 Adalimumab Antibodies Monoclonal Cartilage Chondrogenesis ⋅ Chondrogenic progenitor cells ⋅ Rheumatoid arthritis ⋅ Interleukin 17 (IL‐17) Middle Aged Chondrogenesis 3. Good health 030104 developmental biology Cartilage Cytokines Secukinumab Female Matrix Metalloproteinase 3 Interleukin 17 Immunotherapy Stem cell medicine.symptom |
Zdroj: | European Journal of Immunology |
ISSN: | 1521-4141 |
Popis: | Mesenchymal stem cells are known to exert immunomodulatory effects in inflammatory diseases. Immuneregulatory cells lead to progressive joint destruction in rheumatoid arthritis (RA). Proinflammatory cytokines, such as tumour necrosis factor α (TNF-α) and interleukins (ILs) are the main players. Here, we studied progenitor cells from RA cartilage (RA-CPCs) that are positive for IL-17 receptors to determinate the effects of inflammation on their chondrogenic potenial. IL-17A/F reduced the chondrogenic potential of these cells via the upregulation of RUNX2 protein and enhanced IL-6 protein and MMP3 mRNA levels. Blocking antibodies against IL-17 positively influenced their repair potential. Furthermore, treating the RA-CPCs with the anti-human IL-17 antibody secukinumab or the anti-TNF-α antibody adalimumab reduced the proinflammatory IL-6 protein level and positively influenced the secretion of anti-inflammatory IL-10 protein. Additionally, adalimumab and secukinumab in particular reduced RUNX2 protein to promote chondrogenesis. The amelioration of inflammation, particularly via IL-17 antagonism, might be a new therapeutic approach for enhancing intrinsic cartilage repair mechanisms in RA patients. peerReviewed |
Databáze: | OpenAIRE |
Externí odkaz: |